Text: H.R.3379 — 116th Congress (2019-2020)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (06/20/2019)


116th CONGRESS
1st Session
H. R. 3379


To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.


IN THE HOUSE OF REPRESENTATIVES

June 20, 2019

Ms. Schakowsky (for herself, Mr. Westerman, Ms. DeLauro, Ms. Craig, Mr. Doggett, Mr. Krishnamoorthi, Mr. Khanna, Mr. Cicilline, Mr. Pocan, Mr. Rush, Mr. Levin of Michigan, Mr. Morelle, Ms. Jayapal, Ms. Tlaib, Ms. Kaptur, Mr. Welch, and Mr. García of Illinois) introduced the following bill; which was referred to the Committee on Energy and Commerce


A BILL

To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Price Relief, Innovation, and Competition for Essential Drugs Act” or the “PRICED Act”.

SEC. 2. Exclusivity period for brand name biological products.

(a) In general.—Section 351(k)(7)(A) of the Public Health Service Act (42 U.S.C. 262(k)(7)(A)) is amended by striking “12 years” and inserting “5 years”.

(b) Conforming changes.—Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended by striking “12 years” each place it appears and inserting “5 years”.

(c) Applicability.—This Act and the amendments made by this Act apply only with respect to a biological product for which the reference product (as such term is used in section 351 of the Public Health Service Act (42 U.S.C. 262)) is licensed under subsection (a) of such section on or after the date of enactment of this Act.